Psychosis and schizophrenia in children and young people: recognition and management

New evidence

We found 9 new studies in a search for randomised controlled trials and systematic reviews published between 01 September 2014 and 13 June 2016.

Evidence identified in previous surveillance 2 years after publication of the guideline was also considered. This included 12 studies identified by the Evidence Update and 4 studies identified during the Addendum searches.

From all sources, 25 studies were considered to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A: summary of new evidence from surveillance and references for all new evidence considered.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline and other correspondence we have received since the publication of the guideline.

Views of stakeholders

Stakeholders commented on the decision not to update the guideline. Overall, 5 stakeholders responded and all agreed with the proposal to not update the guideline. See appendix B for stakeholders' comments and our responses.

Three stakeholders provided further comments on the proposal to not update the guideline. Comments highlighted a number of ongoing trials due to publish over the next 2–3 years. These have been noted already and will be considered at the next surveillance review following publication of results. One stakeholder highlighted the lack of guidance for the treatment of comorbid disorders in this population. However, no evidence was identified relating to comorbid disorders in this population therefore no impact on the guideline at this time. A further comment suggested coverage of Open Dialogue and Voice Dialogue treatments. These treatments have already been covered in the surveillance review following identification by a topic expert. However, no evidence was found relating to Open or Voice Dialogue treatments in this population therefore no impact on the guideline at this time.

We requested stakeholders to comment on the removal of 3 priority research recommendations. Stakeholders generally commented that more evidence is needed to answer the research questions. Relevant ongoing trials, which were not previously identified by the surveillance review, were highlighted by stakeholders. These trials will be considered at the next surveillance review when results publish. Having considered the views of topic experts and stakeholders, we propose to retain all the research recommendations in the NICE version of the guideline and the NICE research recommendations database.

Stakeholders were requested to comment on areas excluded from the scope of the guideline and any equalities issues. No comments on equalities issues were made by stakeholders during consultation. However, one stakeholder again raised the issue, as highlighted above, of a lack of guidance around managing comorbid disorders in children and young people.

Overall, we decided not to update the guideline.

See ensuring that published guidelines are current and accurate in 'Developing NICE guidelines: the manual' for more details on our consultation processes.

NICE Surveillance programme project team

Sarah Willett
Associate Director

Philip Alderson
Consultant Clinical Adviser

Katrina Sparrow
Technical Adviser

Omar Moreea
Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-2154-6